Wiskott–Aldrich Syndrome – Market outlook, Epidemiology, Competitive Landscape and Market Forecast Report – 2020 To 2030
Wiskott-Aldrich syndrome (WAS) is an immunological deficiency and reduced ability to form blood clots. Etiology- Wiskott-Aldrich syndrome is caused by mutations in the WAS gene and is inherited in an X-linked manner. Wiskott-Aldrich syndrome, X-linked thrombocytopenia (XLT), and X-linked neutropenia (XLN) are known as “WAS-related disorders” because these diseases are all caused by mutations in the WAS gene. Epidemiology- The estimated prevalence of WAS-related disorders is 3/1,000,000 males. The competitive landscape of Wiskott–Aldrich Syndrome includes country-specific approved and pipeline therapies. Any asset/product-specific designation or review and Accelerated Approval are tracked and supplemented with analyst commentary. KOLs insights of Wiskott–Aldrich Syndrome across 8 MM market from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treat...